1. |
|
2. | Warner RRP. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128, 1668-1684, 2005 |
3. | Norton JA, Warren RS, Kelly MG et al. Aggressive surgery for metastatic neuroendocrine liver tumors. Surgery 134, 1057-1063, 2003 |
4. | Klöppel G, Perren A, Heitz PU. Vom Karzinoid zum neuroendokrinen Tumor. Klassifizierung im Magen-Darm-Trakt und Pankreas. Dtsch Ärztebl 100, 1932-1942, 2003 |
5. | Öberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 44, 3-12, 2000 |
6. | Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 41, 1704-1713, 2000 |
7. |
Jensen RT, Norton JA: Endocrine tumors of the pancreas. In: Feldman M, Scharschmidt BF, Sleisenger MH (eds.), Gastrointestinal and liver disease. Ed.6, 1998, Vol.1, Saunders, Philadelphia, pp 871-894 |
8. |
Klöppel G, Heitz PU, Capella C et al.: Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 20, 132-141, 1996 |
9. | Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncologica 32, 203-208, 1993 |
original articles, Übersichtsartikel, abstracts, reviews, letters, Beiträge
1. | Saddig C, Goretzki PE, Starke AAR Differentiation of insulin secretion patterns in insulinoma. World J Surg 32, 918-929, 2008 |
2.
|
Starke AAR, Hilgers N, Meyer A, Pohl P, Lammers BJ, Saddig C, Goretzki PE. Therapy of non-insulinoma pancreatogenic hypoglycemia syndrome (NIPHS). Exp Clin Endocrinol Diabetes 115, Suppl. 1, S46, 2007 (51. DGE - Jahrestagung, Salzburg 2007) |
3.
|
Starke AAR, Knapp WH, Köster R, Mansfeld L, Goretzki PE. [68Ga]-DOTATOC-PET and visualization of pancreatic islet cell hyperplasia / nesidioblastosis. Exp Clin Endocrinol Diabetes 115, Suppl. 1, S92, 2007 (51. DGE - Jahrestagung, Salzburg 2007) |
4. | Letter : Pradeep PV, Mishra A, Mishra SK - Reply : Starke A |
5. |
Letter: Goretzki PE, Starke AAR. Coincidence of insulinoma with nesidioblastosis or false diagnosis in 2 of 15 patients ? Am J Surg Pathol 30, 919-920, 2006 |
6. OR |
Starke A, Saddig C, Kirch B, Tschahargane C, Goretzki P. Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome (NIPHS). World J Surg 30, 670-679, 2006 |
7. | Starke AAR, Tschahargane C, Goretzki PE. Islet cell hyperplasia in adults - a not so rare cause of pancreatogenic non-insulinoma hypoglycemia. Exp Clin Endocrinol Diabetes 113, Suppl. 1, 2005 (49. DGE - Jahrestagung, Münster März 2005) |
8. OR |
|
9. | Saddig C, Starke AAR. Hypoglykämiediagnostik bei Patienten mit Verdacht auf Insulinom. internist. prax. 43, 43-57, 2003 |
10. | Saddig C, Bender R, Starke AAR. A new classification plot for the C-peptide suppression test. JOP. J.Pancreas (Online) 2002; 3: 16-25; Medline/PubMed ID 11884763 , www.joplink.net/prev/200201/03.html |
11. | Starke AAR, Saddig C. Hypoglykämien im Erwachsenalter. In: Diabetes mellitus. Urban & Fischer, München Jena, 2.Aufl. 2000, S.775-782 |
12. | |
13. | |
14. | Starke AAR. Endokrines Pankreas: Glucagon. In: Kuemmerle, Hitzenberger, Spitzy (Hrsg.): Klinische Pharmakologie - Grundlagen und Methoden der Klinischen Pharmakologie und Pharmakotherapie. 4.Aufl. Ecomed-Verlag, Landsberg, 51. Erg-Lfg. 12/1996, 1-14 |
15. | |
16. | |
17. | Starke AAR. Streptozotozin-Chemotherapie von malignen metastasierenden Insulinomen. In: Lehnert, Kopf, Hensen (Hrsg.), Endokrine Tumoren - Prognostische Parameter, rationelle Diagnostik und Therapie. Bundes- Druckerei, Neu Isenburg 1995, 299-303 |
18. | Starke AAR. "Intraarterielle Calciumprovokation zur präoperativen Lokalisationsdiagnostik des okkulten Insulinoms". Dtsch Med Wschr 118, 881-883, 1993 |
19. | |
20. | Sawicki PT, Heinemann L, Starke A, Berger M. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 35: 649-652, 1992 |
21. | Sawicki PT, Baba T, Berger M, Starke AAR. Normal blood pressure in patients with insulinoma despite hyperinsulinemia and insulin resistance. J Am Soc Nephrol 2, Suppl 4, S64-68, 1992 |
22. | Starke AAR. Das Glucagonom-Syndrom. Int Welt 9: 91-97, 1986 |
Therapie der nicht-funktionellen NET des Pankreas
(non-functional GEP-NET)
1. | Jaeck D, Oussoultzoglou E, Bachelier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 25, 2001, 689-692 |
2. | Matthews BD, Heniford BT, Reardon PR, et al. Surgical experience with non-functioning neuroendocrine tumors of the pancreas. American Surgeon 66, 1116-1123, 2000 |
3. | Lo CY, van Heerden JA, Thompson GB, Grant CS, Soreide JA, Harmsen WS. Islet cell carcinoma of the pancreas. World J Surg 20, 878-884, 1996 |
4. |
Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169, 36-43, 1995 |
5. | White TJ, Edney JA, Thompson JS, Karrer FW, Moor BJ. Is there a prognostic difference between functional and nonfunctional islet cell tumors ? Am J Surg 168, 627-628, 1994 |
6. | Cheslyn-Curtis S, Sitaram V, Williamson RCN. Management of non-functioning neuroendocrine tumors of the pancreas. British J Surg 80, 625-627, 1993 |
7. | Evans DB, Skibber JM, Lee JE, Cleary KR, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114, 1175-1182, 1993 |